Open Access

PGF2alpha induced differential expression of genes involved in turnover of extracellular matrix in rat decidual cells

  • Eduardo A Callegari1, 2,
  • Susan Ferguson-Gottschall1 and
  • Geula Gibori1Email author
Reproductive Biology and Endocrinology20053:3

DOI: 10.1186/1477-7827-3-3

Received: 04 October 2004

Accepted: 11 January 2005

Published: 11 January 2005

Abstract

In the rat, the decidual tissue is an important component for maternal recognition of pregnancy. Decidualization can be induced by either the implantation of the blastocyst or by artificial stimuli. The process of decidua formation or decidualization, is characterized by growth and differentiation of endometrial stromal cells. Prostaglandin F2alpha (PGF2α) has been shown to be involved in inhibition of implantation, alteration of embryo development, induction of luteal regression, and the mediation of pregnancy loss induced by microorganism infections. In order to establish a direct role for PGF2α in decidual function, we have evaluated its effects on the expression of an extensive array of genes using primary decidual cell culture. Upon treatment with PGF2α sixty genes were significantly down-regulated whereas only six genes were up-regulated (from a total of 1176 genes studied). Interestingly, the majority of the genes inhibited by PGF2α are either directly or indirectly involved in the turnover of the extracellular matrix (ECM). Genes such as gelatinase A (MMP2), cathepsin L, tissue inhibitor metalloproteinases 2 (TIMP2) and 3 (TIMP3), plasminogen activator inhibitor1 (PAI1), tissue type plasminogen activator (tPA), urokinase plasminogen activator (tPA), endothelin 1, calponin, carboxypeptidase D and calponin acidic were down regulated. The opposite effect was observed for prostromelysin 53 kDa (proMMP3), plasma proteinase I alpha and alpha 1 antiproteinase, all of which were significantly up-regulated by PGF2α. The results strongly suggest that the abortificient role of elevated levels of PGF2α after implantation is due, in large part, to inhibition of genes involved in the normal turnover of the extracellular matrix necessary for decidual formation.

Background

The establishment of successful pregnancy requires a profound reorganization of uterine tissues. Rapid growth and differentiation of the endometrial stroma is the earliest and most striking event in pregnancy. Differentiation of stromal cells leads to the formation of unique cells, termed decidual cells, which differ greatly from the original stromal cells [1]. The decidua is an important component in the maternal recognition of pregnancy and can be induced by either the implantation of the blastocyst or by artificial stimuli. An interesting feature is that – the growth and differentiation of the endometrial cells – occurs differently in different regions of the uterus [1]. Mesometrial decidual cells are formed after the antimesometrial decidua and their death takes place after antimesometrial cell degeneration. Regression of the decidual cells appears to be controlled by an intrinsic cell death program of apoptosis, which takes place after day 10 of pregnancy in the antimesometrial region first, followed by the mesometrial region [2].

Prostaglandin F can induce different biological actions at the beginning and at the end of pregnancy. PGF, Prostaglandin E2 (PGE2), and 6-keto-PGF are produced by the pregnant uterus [3]. An increase of uterine PGE2 and PGF is observed on day 5 of pregnancy, allowing the decidualization process to take place. When embryo access to the uterus is impaired, production of prostaglandins (PGE2 and PGF) is suppressed [4]. During postimplantation, PGE2 returns to the original preimplantation levels, but PGF decreases [4]. Whereas PGF2α contributes to the process of decidualization, implantation and recognition of pregnancy. An increase in PGF over certain values can terminate pregnancy [6]. A high level of PGF is known to induce inhibition of implantation, alteration of embryo development, and induction of luteal regression [5]. During infection, an inflammatory response mediated by cytokines can be generated [7]. This release of PGF can induce premature uterine contraction and premature labor [8]. Depending on which stage of pregnancy an increase of PGF secretion occurs, it can alter implantation, induce abortion or even embriolethality [7, 8]. Because an increase in PGF levels after implantation can be detrimental for the progression of pregnancy, the aim of this investigation was to determine whether PGF affects directly decidual cells and leads to disturbance in the expression of genes crucial for decidual survival.

Methods

Animal model

Pseudopregnancy was induced by mating Holtzman Sprague Dawley female rats with vasectomized male rats. The day a vaginal plug was found was designated day 1 of pseudopregnancy. Decidualization of the uterine endometrium was induced by scratching the antimesometrial surface with a hooked needle on day 5 of pseudopregnancy under ether anaesthesia. Animals were housed in a controlled environment (22–24°C) and kept under controlled conditions (lights on; 0500–1900 hrs) with free access to standard rat chow and water. The University of Illinois at Chicago animal care and use committee approved the animal care and handling.

Primary decidual cell culture and hormone treatment

For each experiment 15 pseudopregnant rats were used. Decidual cells were isolated as previously described [9]. Cells were pooled and seeded into six-well plates (1.4 × 106 cells/ well). They were allowed to attach 3–4 hrs before washing in PBS to remove erythrocytes. Cells were incubated in RPMI 1640 without phenol red (Mediatech, Whashington DC), containing 1% CD-FBS (HyClone Laboratories Inc, Logan, UT), and treated with or without high levels (5 μM [10, 11]) of PFG (Sigma, St. Louis, MO) for 12 hr). After incubation, the cells were harvested in cold PBS, quick frozen in liquid nitrogen and kept at -80 C until RNA isolation.

Gene identification by cDNA array

Total RNA was isolated from primary decidual cells (PDC) by using a RNAII isolation kit (Clontech, Palo Alto, CA), following the manufacture's instructions. RNA isolated from wells treated with either PGF or vehicle were pooled independently and subjected to cDNA array. cDNA probes were generated from 4 μg of total RNA in a reverse transcriptase reaction using a mix of dATP, dTTP and dGTP (Takara Biomedicals, Shiga, Japan) plus [α32P]-dCTP (Amersham, MO), and a mixture of primers specific to each gene present in the array. All probes used had 5 to 10 × 106 cpm and the difference between control and experimental probes in each assay was less than 10%. cDNA were hybridized to an Atlas Rat 1.2 Array (#7854-1) nylon membrane (Clontech, CA). Hybridization and post-hybridization washes were performed according to the manufacturer's protocol. The signal was scanned with a phosphorImager (Molecular Dynamics, CA) after 48 h of exposure. Control and experimental RNA were always processed in parallel.

Data analysis

Spot intensities from scanned membranes were analyzed using the AtlasImage 1.5 software (Clontech, CA). Grids were orientated manually and adjusted to ensure optimal spot recognition using AtlasImage's fine tuning tools, discarding spots with dust or locally high background. The software makes the analysis for background correction and normalization versus housekeeping genes. It also calculate the ratio and indicates which genes has a ratio > 2 (up regulated), or ratio < 0.5 (down regulated) or 0.5 < ratio < 2 (equal expression). Gene expression data were normalized using the Sum method included in the Atlas Image software. Data points where the expression was not greater than two standard deviations were discarded. For the final analysis, data points were the averages from triplicates and any non-reproducible data were discarded. The relative RNA expression with differences between control and treatment being higher or equal to 2 and lower than 0.5 were considered significantly different [12].

Results

Effect of PGF on gene expression in primary decidual cells

From the total genes available in the rat 1.2 membrane arrays, only 20% of the genes were detected in rat primary decidual cells. Sixty genes were significantly down regulated, whereas only six genes were up regulated by PGF (Figures 1 and 2). PGF-receptor gene expression was similar in both control and treated groups. On the other hand, no differences in the expression of housekeeping genes such as ribosomal proteins and β-actin could be detectedin control and PGF treated cells (data not shown).
Figure 1

Representative cDNA expression array using mRNA obtained from rat primary decidual cells treated with either PGF or vehicle.

Figure 2

cDNA expression array of rat primary decidual cells treated with PGF or vehicle.

Effect of PGF on the expression of genes related to the extracellular matrix (ECM)

The majority of genes whose expression was affected by PGF in primary decidual cells are genes involved in the regulation of the ECM. Genes such as gelatinase A (MMP2), cathepsin L, tissue inhibitor metalloproteinases 2 (TIMP2) and 3 (TIMP3), plasminogen activator inhibitor1 (PAI1), tissue type plasminogen activator (tPA), urokinase plasminogen activator (uPA), endothelin 1, calponin, carboxypeptidase D and calponin acidic were down regulated. The opposite effect was observed for prostromelysin 53 kDa (proMMP3), plasma proteinase I alpha and alpha 1 antiproteinase – all of which were significantly up regulated by PGF (Table 1).
Table 1

Effect of PGF on the expression of genes related to the extracellular matrix (ECM).

Gene Bank number

Swiss protein number

Name

Function

Ratio

% decrease

Fold increase

U65656

P97581

Gelatinase A

Metalloproteinase

0.04 ± 0.02

87.53

 

Y00697

P07154

Cathepsin L

Cysteine protease

0.09 ± 0.05

91.09

 

L31884

P30121

Tissue inhibitor metalloproteinase 2 (TIMP2)

Protease inhibitor

0.05 ± 0.01

95.54

 

U27201

P48032

Tissue inhibitor metalloproteinase 3 (TIMP3)

Protease inhibitor

0.04 ± 0.01

91.95

 

X63434

P29598

Urokinase type Plasminogen activator (uPA)

Serine protease

0.14 ± 0.09

94.86

 

M24067

P20961

Plasminogen activator inhibitor (PAI)

Protease inhibitor

0.09 ± 0.05

91.68

 

M2367

P19367

Tissue type plasminogen activator (tPA)

Serine protease

0.17 ± 0.02

89.90

 

X71071

Q08290

Calponin

Cytoskeleton

0.08 ± 0.004

92.50

 

U06755

P37397

Calponin, acidic

Cytoskeleton

0.24 ± 0.13

76.76

 

U62897

O35850

Carboxypeptidase D

Carboxypeptidase

0.24 ± 0.14

76.48

 

M64711

P22388

Endothelin 1

Hormone

0.34 ± 0.2

77.48

 

X02601

P03957

Polypeptide, 53 kDa, growth factor induced

Metalloproteinase

2.54 ± 1.04

 

3

J03552

P14046

Plasma proteinase inhibitor α1-inhibitor III

Protease inhibitor

3.64 ± 0.64

 

4

M32247

P17475

α1 antiproteinase

Protease inhibitor

2.45 ± 0.44

 

3

Ratio = net intensity of PGF normalized/net intensity of control normalized, and represent the mean ± SEM of each ratio from separate experiments. Ratio > 2 = up regulation; ratio < 0.5 = down regulation; 0.5 < Ratio < 2 = equal expression.

PGF regulation of genes related to the proteasome protein component system

Messenger RNA encoding proteasome Iota, proteasome component C2, proteasome subunit RC7-I, 26-S proteasome regulator and proteasome component C3 were down regulated by PGF. Only proteasome component C9 was up regulated after PGF treatment (Table 2).
Table 2

PGF regulation of genes related to the proteasome component system.

Gene Bank number

Swiss Protein number

Name

Function

Ratio

% decrease

Fold increase

D10755

P34062

Proteasome Iota

Proteosomal protein

0.07 ± 0.04

93.64

 

M29859

P18420

Proteasome component C2

Proteosomal protein

0.31 ± 0.15

78.28

 

U77918

Q63569

26-proteasome component C3

Proteosomal protein

0.39 ± 0.08

61.94

 

J02897

P17220

Proteasome component C3

Proteosomal protein

0.31 ± 0.02

59.02

 

D21799

P40307

Proteasome subunit RC7-I

Proteosomal protein

0.18 ± 0.01

82.62

 

X55986

P21670

Proteasome subunit C9

Proteosomal protein

2.32 ± 0.72

 

3

PGF regulation of genes involved in trafficking and signal transduction

The mRNAs encoding for 14-3-3ε and z/δ proteins, and Annexin IV were down regulated in PDC after PGF treatment (Table 3). PGF down regulated the expression of serum glucocorticoid kinase (SGK), casein kinase I, extracellular signal-regulated kinase (ERK-1), male germ cell-associated kinase (MAK), and Wee tyrosine kinase. PGF also significantly inhibited Crk-associated kinase (CAS), calcium calmodulin kinase II (CAMKII) and IV (CAMKIV), phospholipase C1, and protein phosphatases such as phosphatase 2A and protein tyrosine phosphatase 1B (Table 3).
Table 3

PGF regulation of genes encoding proteins involved in trafficking and signal transduction.

Gene Bank number

Swiss protein number

Name

Function

Ratio

% decrease

Fold increase

D17615

P97286

14-3-3 z/δ protein

Traficking protein

0.14 ± 0.07

86.07

 

M84416

P29360

14-3-3 Epsilon protein

Traficking protein

0.29 ± 0.15

71.63

 

L01624

Q06226

Serum Glucocorticoid kinase (SGK)

Kinase

0.25 ± 0.12

93.49

 

L07578

Q06486

Casein kinase I δ

Kinase

0.29 ± 0.15

72.18

 

M61177

P21708

Extracellular signal-regulated kinase 1 (ERK1)

Kinase

0.29 ± 0.13

66.67

 

D29766

Q63766

Crk-associated kinase

Kinase

0.09 ± 0.06

87.16

 

M35862

P20793

Male germ cell-associated kinase (Mak)

Kinase

0.20 ± 0.11

78.6

 

D31838

Q63802

Wee tyrosine kinase

Cell cycle kinase

0.23 ± 0.12

69.47

 

M20637

P10688

Phospholipase C δ1

Phospholipase PI kinase

031 ± 0.15

68.24

 

J04503

P20650

Protein phosphatase 2C α

Phosphatase

0.18 ± 0.03

58.87

 

L12385

P26438

Protein Phosphatase 2A

Phosphatase

0.38 ± 0.13

65.91

 

L13408

P15791

Ca+2/Calmodulin dependent kinase II δ subunit

Kinase

0.34 ± 0.12

72.12

 

M63334

P13234

Ca+2/Calmodulin dependent kinase IV

Kinase

0.29 ± 0.15

70.90

 

M33962

P20417

Protein Tyrosine phosphatase 1B

Phosphatase

0.21 ± 0.08

79.77

 

D38224

P55260

Annexin IV (ANX4)

Exocytosis protein

0.14 ± 0.08

86.34

 

L24810

Q64572

Ca+2/Calmodulin Phosphorylase B

Kinase

5.06 ± 2.06

 

5

PGF2α effect on the expression of genes associated with G-proteins, growth factors, chemokines and cytokines

The 5-hydroxytryptamine receptor 2A (HTR2A), adenosine A2A and A2B receptors (ADORA2A and ADORA2B respectively), guanine nucleotide-binding protein G α3 subunit (GN-BPG α3), guanine nucleotide-binding protein α stimulating (GN-BP α stimul.), Rab 11A and guanine nucleotide-binding protein α12 subunit (GN-BP α12) gene expression were down regulated by PGF (Table 4). The mRNA expression of growth factors such as bone morphogenetic protein 4 (BMP4), ADP ribosylation factor 5 and 6 (ADPRF5 and 6 respectively), glia maturation factor β (GMFB), and transforming growth factor β I (TGF-βI) decreased after PGF treatment as well (Table 1). Interferon inducible protein (Table 4) and leukocyte common antigen (data not shown) were the only cytokine and chemokine related genes found significantly down regulated in response to PGF. Conversely, PGF stimulated the expression of basic fibroblast growth receptor factor 1 (bFGRF1) (Table 4).
Table 4

Effect of PGF on the expression of genes associated with G-proteins, growth factors, chemokines and cytokines.

Gene Bank number

Swiss protein number

Name

Function

Ratio

% decrease

Fold change

X52498

P17246

Transforming Growth Factor β1

Growth factor

0.33 ± 0.2

72

 

M60921

P27049

Antiproliferative B-cell translocation gene 2 (BTG2)

Growth factor

0.28 ± 0.15

51

 

X61381

P26376

Interferon-induced protein

Chemokine

0.25 ± 0.14

56

 

L11586

Q64604

Leukocyte common antigen

Intracell. phosphatase

0.07 ± 0.02

83

 

Z22607

Q06826

Bone Morphogenetic protein 4 (BMP4)

Growth factor

0.34 ± 0.17

78

 

L12384

P26437

ADP Ribosylation factor 5

Intracellular transducer

0.02 ± 0.008

67

 

L12385

P26438

ADP Ribosylation factor 6

Intracellular transducer

0.18 ± 0.07

83

 

Z11558

Q63228

Glia maturation factor β (GMFB)

Growth factor

0.17 ± 0.07

83

 

M30705

P14842

5-hydroxytryptamine receptor 2A (HTR2A)

G proteins

0.06 ± 0.03

93

 

S47609

P30543

Adenosine A2A receptor (ADORA2A)

G proteins

0.13 ± 0.08

87

 

M91466

P29276

Adenosine A2B receptor (ADORA2B)

G proteins

0.17 ± 0.07

83

 

M20713

P08753

Guanine nucleotide-binding protein G α3 subunit

G proteins

0.22 ± 0.14

78

 

M17525

P04894

Guanine nucleotide-binding protein α stimulating

G proteins

0.24 ± 0.13

75

 

M75153

P24410

Rab-11A

G proteins

0.18 ± 0.11

82.

 

D85760

Q63210

Guanine nucleotide-binding protein α12 subunit

G proteins

0.15 ± 0.09

85

 

D12498

Q04589

Basic Fibroblast Growth Receptor factor 1

Growth factor

2.32 ± 1.07

 

3

Discussion

Levels of PGF in the uterus need to be under tight control to avoid interference with the establishment and progression of pregnancy. Pathophysiological elevations in PGF lead to excessive uterine contractions. Therefore, PGF production must be avoided to maintain a quiescent uterus [13]. In this paper we present initial data demonstrating that elevated PGF can target the decidua, an endocrine tissue whose integrity is fundamental for the success of implantation and for the progression of pregnancy. Our results demonstrate that elevated PGF down regulate the expression of decidual genes related to the proteasome protein component system, those involved in trafficking and signal transduction and genes associated with G-proteins, growth factors, chemokines and cytokines. However, interestingly, the main effect of PGF is related to the turnover and degradation of the ECM which provides mechanical strength to the tissue. Thus, in addition to inducing uterine contractions, PGF can have a noxious impact on the success of implantation and progression of pregnancy, at least in part by deregulating the turnover of the ECM in the decidua.

The largest group of genes down regulated by PGF is directly or indirectly related with the turnover and degradation of the ECM. Genes such as gelatinase A (MMP-2), TIMP2 and 3 [14, 15], cathepsin L [16], carboxypeptidase D are included in different groups of proteases, and can directly affect the degradation of the ECM. Carboxypeptidase D (CPD) or metallocarboxypeptidase D is a 180-kDa protein that contains almost three carboxypeptidase-like domains, a transmembrane domain, and a cytosolic tail. This gene participates in the processing of proteins transiting the secretory pathway [17]. TGF-β is a key factor that favours accumulation of collagen, laminin and fibronectin in the ECM [17]. TGF-β can stimulate PAI-1, inhibiting the protease degradation of the ECM. Other factors included in the plasminogen/plasmin and fibrinolytic system, such as tPA, uPA and PAI-1, can participate in the tissue remodelling of the ECM directly through the binding to specific receptors, and through the transformation of the plasminogen precursor bound to the cell surface to plasmin, which is an active serine protease. Plasmin is able to degrade most of the components of the ECM either directly or indirectly by the activation of MMPs. All of the plasminogen/plasmin factors mentioned previously participate in the process of decidualization [1921].

Endothelin-1 is a peptide characterized as a potent endothelial cell-derived vasoconstrictor. It is synthesized as an inactive precursor (preproendothelin) and processed to a mature active form (endothelin) by zinc metalloproteinases. The active form, endothelin-1, promotes synthesis of collagen types I and II by fibroblasts, affects the ECM remodelling and promotes the proliferation of mesangial cells [21]. Endothelin-1 is also associated with neovascularization and regulation of blood flow [22]. This vasoactive factor is also involved in the genesis of endothelial cells behaviour [22, 23].

Annexin IV (ANX4, also called Lipocortin) was differentially down regulated by PGF. This protein belongs to a family of intracellular proteins that binds membrane phospholipids in a calcium-dependent manner. Thus, it can also inhibit phospholipase A2 (PLA2) [24]. ANX4 can also directly bind glycosaminoglycan (GAG) and can be localized not only to the cytoplasm but also the cell surface or the extracellular compartment [25]. It has been proposed that ANX4 could affect the mobilization of different substrates involved in the regulation of the ECM. Moreover, Annexin IV and other annexins can act as ligands for proteoglycans localized on the cell surface, in the ECM, or in secretory granules [24, 25].

Calponin (CaP) has three genetic isoforms, h1, h2 and acidic calponin, and can be identified by the individual C-terminal tail sequences. The c-terminal sequences regulate actin association and the cytoskeleton [26, 27]. It is known that Cap or basic Cap inhibit the actomyosin ATPase in a calmodulin dependent manner [27]. Basic Cap, by affecting microtubules assembly, can modify the cytoskeleton of the cells, and indirectly, the associated ECM [27, 28]. On the other hand, acidic Cap belongs to the family of actin-associated proteins. It can interact with F-actin but not with microtubules, desmin filaments, and tropomyosin as basic Cap does. These properties suggest that acidic Cap is functionally distinct from basic Cap and could affect the ECM in a different manner [29].

Pro-stromelysin, α1 antiproteinase, plasma proteinase-Iα inhibitor, basic fibroblast growth receptor factor 1, phosphorylase B and proteasome component C9 were the only genes up regulated by PGF in PDC. Pro-stromelysin is a 53 kDa peptide and a pro-MMP3 precursor and is directly related with the ECM regulation [30]. Plasma proteinase 1α inhibitor belongs to a major group of proteins that includes α2-macroglobulin [31], an important protein secreted by the decidual cells which has a critical role in the control of implantation [31]. Growth factor receptors, such as bFGRF, are part of a multigene family of structurally related factors (FGFs 1 to 9), some of which bind heparin sulphate proteoglycans that are components of the ECM [32]. bFGRFs as well as bFGF are also temporally and spatially present in the pregnant rat uterus [3335]. Another member of the TGFβ superfamily expressed in the uterus during early implantation and down-regulated by PGF was BMP4, a gene which appears to be involved in specific stages of embryo development and is [36].

Proteasome component system proteins, such as proteasome Iota, proteasome component C2, proteasome subunit RC-7 I, 26 S-proteasome and proteasome component C3 were down regulated by PGF. Proteosomal component systems are the main non-lysosomal proteolytic structures of the cells that participate in the elimination of abnormal proteins, short half-life proteins, and proteins controlling cell cycle [37]. During the process of cell differentiation, the level of proteasome expression and its localization varies. The proteasomal proteins can be intermediaries of ECM by contributing to the modulation of the cell cycle through the induction of proteasomal degradation of cyclin dependent kinase 2. Cell attachment to ECM components, such as fibronectin (FN), does not affect p21 mRNA levels, but the stability of the p21 protein decreased [36]. Kinase activities such as ERKs, calcium/calmodulin kinase II and IV, SGK, and casein kinase can affect the ECM downstream or upstream [38]. On the other hand, ECM can regulate the availability of substrates, as well as factors or effectors downstream or upstream related with different cascades of signal transduction pathways. For example, proteins such as decorin are components of the ECM in many tissues and appear to be involved in matrix assembly [39]. Decorin can cause the rapid phosphorylation of EGF with the concurrent activation of mitogen-activated kinase protein kinase signal pathway. Via TGFβ, decorin can interact with the MAP kinases signal transduction pathways and cross talk with calcium /calmodulin-dependent kinase II [40], which in the cDNA array was down-regulated by PGF.

Crk-associated substrate (CAS) was down-regulated by PGF and is another gene related to the ECM. Active CAS can modulate changes in cell motility and gene expression by the various MAP kinase cascades, and modify the organization of the actin cytoskeleton [39]. Another gene down-regulated by PGF was SGK, which is a transcriptionally-regulated serine/threonine protein kinase with 45–55% homology to the catalytic domain of Akt/PKB protein kinase A [40]. Skg is expressed in decidual tissue and can be activated by the phosphoinositide 3-kinase pathway (PI3-Kinase) through PDK1-mediated phosphorylation [41]. Traficking proteins such as 14-3-3 z/δ and ε are involved in the regulation of genes related to the ECM because it can block the activation cascade of signal transduction pathways [42].

Protein phosphatase type 2A (PP2A) was down regulated by PGF. The first and most important point of control of PP2A is at the transcriptional level. The increase of phosphatase activity corresponded with a decrease in the phosphorylation of cellular proteins in anchorage-dependent cells, but much lesser regulated in anchorage-independent cells [43].

It is well known that members of the proinflammatory cytokine family can induce MMP expression in numerous tissues [44]. Also, cytokines and chemokines, such as interferon inducible protein and leukocyte common antigen, are associated with the local induction of MMP expression in response to proinflammatory cytokines. The indirect action of these molecules through MMPs may aid to generate different changes in the endometrial stroma during maternal recognition of pregnancy [44]

We have also compared the pattern of gene expression in rat decidual tissue in vivo on day 12 of pseudopregnancy (when the decidua undergoes regression) with that of the PGF treatment in rat PDC in vitro (data not shown). Interestingly, we found a 49% coincidence in the genes that were down regulated in both experimental situations. This coincidence suggests a relationship between the physiological regression and reorganization of the decidual tissue that occurs on day 12 of pseudopregnancy, with the pattern of gene expression in rat PDC after PGF treatment. On the other hand, many of the genes whose expression was affected by PGF in the rat PDC, are expressed in the decidua during decidualization and implantation. This suggests a possible connection between the action of PGF and the physiology of the decidual tissue. Moreover, the ECM is an important component of the decidualization and implantation process. Any modification in its turnover or degradation could affect the formation of the decidua, blastocyst invasion, and the timing of decidual regression and reorganization. It is known that the expression of MMPs/TIMPs plays an important role in the control of implantation. If PGF silences or decreases the expression of genes related with the systems aforementioned, it also could affect tissue remodelling by directly modifying the proteases involved in this process, or indirectly by affecting the ECM turnover and degradation, important in the accumulation of a spongy mass of tissue around each embryo during decidualization [45]. Most probably, many of PGF's effects on the expression of genes involved in ECM turnover are indirect. Alterations of genes involved in different signalling pathways such as ERK-1, CaMCKII, PLCδ1 and G-protein subunits may impact the expression of a great number of transcripts.

In summary, our results show, for the first time, that pathophysiological concentrations of PGF have a severe impact on the expression of numerous genes associated with the turnover of the ECM in the rat decidua. Future investigation should corroborate the differentially regulated genes, at the level of the message, protein, and in some cases, such as for the metalloproteinases, at the level of activity of the proteins. These data will contribute to the design of future studies on a cluster of gene candidates as targets of PGF action in this endocrine tissue.

Figure 3

PGF has major effects on extracellular matrix (ECM) regulation

Abbreviations

TIMP2: 

= tissue inhibitor metalloproteinases 2

TIMP3 : 

= tissue inhibitor metalloproteinases 3

PAI 1 : 

= plasminogen activator inhibitor 1

uPA : 

= urokinase type

tPA : 

= tissue type palsminogen activator

TGFβ : 

= transforming growth factor β

SGK : 

= serum glucocorticoid kinase

ERK-1: 

= extracellular signal-regulated kinase-1

MAK : 

= male germ cell-associated kinase

CAS : 

= crk-associated kinase kinase

CamKII : 

= calcium calmodulin kinase II

CamKIV : 

= calcium calmodulin kinase IV

PLC δ1

= phospholipase C delta 1

BMP 4 : 

= bone morphogenetic factor 4

ADPRF 5 : 

= ADP ribosylation factor 5

bFGFRF1 : 

= basic fibroblast growth factor receptor F1

HTR2A : 

= 5-hydroxytryptamine receptor 2A

ADORA2A : 

= adenosine receptor A2A

ADORA2B : 

= adenosine receptor A2B

GN-BPG α3

= guanine nucleotide-binding protein G α3

GN-BP α stimul.: 

= guanine nucleotide-binding protein α stimulating

GN-BPG α12 sub.: 

= guanine nucleotide-binding protein α12 subunit

Declarations

Acknowledgements

This research was supported by NIH grant number NIH HD 12356 and NIH, U54 HD 40093. We thank Dr. CM Telleria and Gil Gibori for constructive reading of the manuscript.

Authors’ Affiliations

(1)
Department of Physiology and Biophysics, University of Illinois at Chicago
(2)
Biomedical Resources Infrastructure Network (BRIN), Division of Basic Biomedical Sciences, The University of South Dakota School of Medicine

References

  1. Gu Y, Srivatstava RK, Clarke DL, Linzer DIH, Gibori G: The decidual Prolactin receptor and its regulation by Decidua-Derived Factors. Endocrinology. 1996, 137: 4878-4885. 10.1210/en.137.11.4878.PubMedGoogle Scholar
  2. Gu Y, Jow GM, Moulton BC, Lee C, Sensibar JA, Park-Sarge OK, Chen TJ, Gibori G: Apoptosis in decidual tissue regression and reorganization. Endocrinology. 1994, 135: 1272-9. 10.1210/en.135.3.1272.PubMedGoogle Scholar
  3. Novaro V, Rettori V, Gonzalez ET, Jawerbaum A, Faletti A, Canteros G, de Gimeno MA: Interaction between uterine PGE and PGF2 alpha production and the nitridergic system during embryonic implantation in the rat. Prostaglandins. 1996, 51: 363-76. 10.1016/0090-6980(96)00043-3.View ArticlePubMedGoogle Scholar
  4. Motta AB, Franchi AM, Gimeno MF: Role of nitric oxide on uterine and ovarian prostaglandin synthesis during luteolysis in the rat. Prostaglandins Leukot Essent Fatty Acids. 1997, 56: 265-9. 10.1016/S0952-3278(97)90569-X.View ArticlePubMedGoogle Scholar
  5. Stocco CO, Deis RP: Participation of intraluteal progesterone and prostaglandin F2 alpha in LH-induced luteolysis in pregnant rat. J Endocrinol. 1998, 156: 253-9. 10.1677/joe.0.1560253.View ArticlePubMedGoogle Scholar
  6. Bany BM, Kennedy TG: Interleukin-1 alpha regulates prostaglandin production and cyclooxygenase in sensitized rat endometrial stromal cells in vitro. Biol Reprod. 1995, 53: 126-132.View ArticlePubMedGoogle Scholar
  7. Marks TA, Tracy DE: Prevention of human recombinant interleukin-1 beta (rhIL-1 beta) embryolethality with progesterone or indomethacin. Am J Reprod Immunol. 1995, 33: 292-300.View ArticlePubMedGoogle Scholar
  8. Bany BM, Kennedy TG: Regulation by epidermal growth factor of prostaglandin production and cyclooxygenase activity in sensitized rat endometrial stromal cells in vitro. J Reprod Fertil. 1995, 104: 57-62.View ArticlePubMedGoogle Scholar
  9. Gu Y, Gibori G: Isolation, culture, and characterization of the two cell subpopulations forming the rat decidua: differential gene expression for activin, follistatin, and decidual prolactin-related protein. Endocrinology. 1995, 136: 2451-2458. 10.1210/en.136.6.2451.PubMedGoogle Scholar
  10. Schrey MP, Monaghan H, Holt JR: Interaction of paracrine factors during labour: interleukin-1 beta causes amplification of decidua cell prostaglandin F2 alpha production in response to bradykinin and epidermal growth factor. Prostaglandins Leukot Essent Fatty Acids. 1992, 45: 137-42. 10.1016/0952-3278(92)90230-G.View ArticlePubMedGoogle Scholar
  11. Stocco CO, Lau LF, Gibori G: A calcium/calmodulin-dependent activation of ERK – mediates Jun D phosphorylation and induction of Nur 77 and 20-alpha-hsd genes by prostaglandin F2alpha in ovarian cells. J Biol Chem. 2002, 277: 3293-3302. 10.1074/jbc.M110936200.View ArticlePubMedGoogle Scholar
  12. Stocco C, Callegari E, Gibori G: Opposite effect of Prolactin and Prostaglandin F on the expression of luteal genes as revealed by rat cDNA expression array. Endocrinology. 2001, 142: 4158-4161. 10.1210/en.142.9.4158.PubMedGoogle Scholar
  13. Farina M, Ribeiro ML, Weissman C, Estevez A, Billi S, Vercelli C, Franchi A: Biosynthesis and catabolism of prostaglandin F2 (alpha) (PGF) are controlled by progesterone in the rat uterus during pregnancy. J Steroid Biochem Mol Biol. 2004, 91: 211-218. 10.1016/j.jsbmb.2004.05.001.View ArticlePubMedGoogle Scholar
  14. Nuttall RK, Kennedy TG: Gelatinases A and B and Tissue Inhibitors of Metalloproteinases 1, 2, and 3 during In Vivo and In Vitro decidualization of rat endometrial stromal cells. Biol Reprod. 1999, 60: 471-478.View ArticlePubMedGoogle Scholar
  15. Hurst PR, Palmay RD: Matrix metalloproteinases and their endogenous inhibitors during the implantation period in the rat uterus. Reprod Fertil Dev. 1999, 11: 395-402. 10.1071/RD99021.View ArticlePubMedGoogle Scholar
  16. Alfonso S, Romagnano L, Babiarz B: The expression and function of cystatin C and cathepsin B and L during mouse embryo implantation and placentation. Development. 1997, 124: 3415-3425.Google Scholar
  17. Kalinina E, Varlamov O, Fricker LD: Analysis of the carboxypeptidase D cytoplasmic domain: implications in intracellular trafficking. J Cell Biochem. 2002, 85: 101-111.View ArticlePubMedGoogle Scholar
  18. Bischof P: Endocrine, paracrine and autocrine regulation of trophoblastic metalloproteinase. Early Pregnancy. 2001, 5: 30-31.PubMedGoogle Scholar
  19. Zhang X, Shu MA, Ross HE, Kennedy TG: Regulation of plasminogen activator in rat endometrial stromal cells: the role of Prostaglandin E2. Biol Reprod. 1996, 54: 1046-1051.View ArticlePubMedGoogle Scholar
  20. Bogic LV, Ohira RH, Yamamoto SY, Okazaki KJ, Millar K, Bryant-Greenwood GD: Tissue plasminogen activator and its receptor in the human amnion, chorion, and deciduas at preterm and term. Biol Reprod. 1999, 60: 1006-1012.View ArticlePubMedGoogle Scholar
  21. Wang S, Kennedy TG, Zhang X: Presence of urokinase plasminogen activator and plasminogen activator inhibitor-1 messenger ribonucleic acids in rat endometrium during decidualization in vivo. Biol Reprod. 1996, 55: 493-497.View ArticlePubMedGoogle Scholar
  22. Shi-wen X, Denton CP, Dashwood MR, Holmes AM, Bou-Gharios G, Pearson JD, Black CM, Abraham DJ: Fibroblast matrix gene expression and connective tissue remodelling: role of endothelin-1. J Invest Dermatol. 2001, 116: 417-425. 10.1046/j.1523-1747.2001.01256.x.View ArticlePubMedGoogle Scholar
  23. Kitamura A, Kagami S, Urushihara M, Kondo S, Yoshizumi M, Tamaki T, Kuroda Y: Endothelin-1 is a potent stimulator of α1β1 integrin-mediated collagen matrix remodeling by rat mesangial cells. Biochem Biophys Res Commun. 2002, 299: 555-561. 10.1016/S0006-291X(02)02693-1.View ArticlePubMedGoogle Scholar
  24. Bandorowicz-Pikuta J, Awashi YC: Interaction of annexins IV and VI with ATP. An alternative mechanism by which a cellular function of these calcium- and membrane-binding proteins is regulated. FEBS Lett. 1997, 409: 300-306. 10.1016/S0014-5793(97)00534-6.View ArticleGoogle Scholar
  25. Ishitsuka R, Kojima K, Utsumi H, Ogawa H, Matsumoto I: Glysosaminglycan Binding Properties of Annexin IV, V, and VI. J Biol Chem. 1998, 273: 9935-9941. 10.1074/jbc.273.16.9935.View ArticlePubMedGoogle Scholar
  26. Jin JP, Wu D, Gao J, Nigam R, Kwong S: Expression and purification of the h1 and h2 isoforms of calponin. Protein Expr Purif. 2003, 31: 231-239. 10.1016/S1046-5928(03)00185-2.View ArticlePubMedGoogle Scholar
  27. Fattoum A, Roustan C, Smyczynski C, Der Terrossian E, Kassab R: Mapping the microtubule binding regions of calponin. Biochemistry. 2003, 42: 1274-1282. 10.1021/bi020336g.View ArticlePubMedGoogle Scholar
  28. Ueki N, Ohkawa T, Yamamura H, Takahashi K, Tsutsui T, Kawai Y, Yokoyama Y, Amuro Y, Hada T, Higashino K: Induction of calponin-h1 by transforming growth factor-beta1 in cultured human ito cells, LI90. Biochim Biophys Acta. 1998, 1403: 28-36. 10.1016/S0167-4889(98)00015-9.View ArticlePubMedGoogle Scholar
  29. Fujii T, Yabe S, Nakamura K, Koizumi Y: Functional analysis of rat acidic calponin. Biol Pharm Bull. 2002, 25: 573-579. 10.1248/bpb.25.573.View ArticlePubMedGoogle Scholar
  30. Umenishi F, Yasumitsu H, Ashida Y, Yamauti J, Umeda M, Miyazaki K: Purification and properties of extracellular matrix-degrading metallo-proteinase overproduced by Rous sarcoma virus-transformed rat live cell line, and its identification as transin. J Biochem. 1990, 108: 537-543.PubMedGoogle Scholar
  31. Athauda SB, Nishigai M, Arakawa H, Ikai A, Ukai M, Takahashi K: Inhibition of human pepsin and gastricsin by alpha2-macroglobulin. J Enzyme Inhib Med Chem. 2003, 18: 219-224. 10.1080/1475636031000101246.View ArticlePubMedGoogle Scholar
  32. Powell PP, Wang CC, Horinouchi H, Shepherd K, Jacobson M, Lipson M, Jones R: Differential Expression of Fibroblast Growth Factor Receptors 1 to 4 and Ligand Genes in Late Fetal and Early Postnatal Rat Lung. Am J Respir Cell Mol Biol. 1998, 19: 563-572.View ArticlePubMedGoogle Scholar
  33. Barkai U, Prigent-Tessier A, Tessier C, Gibori GB, Gibori G: Involvement of SOCS-1, the suppressor of cytokine signaling, in the prevention of prolactin-responsive gene expression in decidual cells. Mol Endocrinol. 2000, 14: 554-563. 10.1210/me.14.4.554.View ArticlePubMedGoogle Scholar
  34. Rider V, Piva M, Cohen ME, Carlone DL: Alternative splicing and differential targeting of fibroblast growth factor receptor 1 in the pregnant rat uterus. Endocrinology. 1995, 136: 3137-3145. 10.1210/en.136.7.3137.PubMedGoogle Scholar
  35. Srivastava RK, Gu Y, Ayloo S, Zilberstein M, Gibori G: Developmental expression and regulation of basic fibroblast growth factor and vascular endothelial growth factor in rat deciduas and in a decidual cell line. J Mol Endocrinology. 1998, 21: 355-362. 10.1677/jme.0.0210355.View ArticleGoogle Scholar
  36. Lillien L, Raphael H: BMP and FGF regulate the development of EGF-responsive neural progenitor cells. Development. 2000, 127: 4993-5005.PubMedGoogle Scholar
  37. Lavabre-Bertrand T, Henry L, Guiraud I, Carillo S, Bureau JP: The Proteasome and malignant hemopathies. Morphologie. 2000, 84: 39-43.PubMedGoogle Scholar
  38. Gao ZH, Seeling JM, Hill V, Yochum A, Virshup DM: Casein Kinase I phosphorylates and destabilizes the beta-catenin degradation complex. Proc Natl Acad Sci USA. 2002, 99: 1182-1187. 10.1073/pnas.032468199.PubMed CentralView ArticlePubMedGoogle Scholar
  39. Turner CE: Paxillin interactions. J Cell Sci. 2000, 113: 4139-4140.PubMedGoogle Scholar
  40. Abdel-Wahab N, Wicks SJ, Mason RM, Chantry A: Decorin suppresses transforming growth factor-β-induced expression of plasminogen activator inhibitor-1 in human mesangial cells through a mechanism that involves Ca+2-dependent phosphorylation of Smad2 at serine-240. Biochem J. 2002, 382: 643-649. 10.1042/0264-6021:3620643.View ArticleGoogle Scholar
  41. Lee E, Lein ES, Firestone GL: Tissue-specific expresión of the transcriptionally regulated serum and glucocorticoid-inducible protein kinase (Sgk) during mouse embryogenesis. Mech Dev. 2001, 103: 177-181. 10.1016/S0925-4773(01)00351-3.View ArticlePubMedGoogle Scholar
  42. Santoro MM, Gaudino G, Marchisio PC: The MSP receptor regulates alpha 6 beta 4 and alpha 3 beta 1 integrins via 14-3-3 proteins in keratinocyte migration. Dev Cell. 2003, 5: 257-271. 10.1016/S1534-5807(03)00201-6.View ArticlePubMedGoogle Scholar
  43. Villalobos Campos S, Schonthal AH: Induction of protein phosphatase 2A in response to disruption of cell-matrix interactions. J Cell Physiol. 2000, 182: 88-86.View ArticlePubMedGoogle Scholar
  44. Curry TE, Osteen KG: The Matrix Metalloproteinase System: Changes, Regulation, and Impact throughout the Ovarian and Uterine Reproductive Cycle. Endocr Rev. 2003, 24: 428-465. 10.1210/er.2002-0005.View ArticlePubMedGoogle Scholar
  45. Paria BC, Ma W-g, Tan J, Raja S, Das SK, Dey SK, Hogan LM: Cellular and molecular reponses of the uterus to embryo implantation can be elicited by locally applied growth factors. Proc Nat Acad Sci USA. 2001, 98: 1047-1052. 10.1073/pnas.98.3.1047.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Callegari et al; licensee BioMed Central Ltd. 2005

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement